| Name | Title | Contact Details |
|---|
Accupac has proven to be a leader in the contract manufacturing of a variety of medical devices. Our syringe technology is just one example. We have the capability to manufacture the product, fill, label and then seal the syringe into a thermoform tray
At Horizon Therapeutics, we believe science and compassion must work together to transform lives. We are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. For us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.
Apex Clinical is a Apex, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB`s versatile DiversitAb™ platform is appliable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has a number of collaborations with the US government and global pharmaceutical companies.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns` programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. Terns` investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.